Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 110-113
DOI: 10.4103/ijmpo.ijmpo_104_20
Editorial Commentary

Novel Coronavirus Severe Acute Respiratory Syndrome-Coronavirus 2 (Coronavirus Disease 2019): We Shall Overcome!

Padmaj Kulkarni
Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
,
Manikandan Dhanushkodi
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

India is currently in the second stage of the coronavirus disease 2019 (COVID-19) pandemic. It all started in December 2019 when there was a cluster of patients with pneumonia in Wuhan, the capital of Hubei province in China. Investigators found that it was caused by a new strain of coronavirus known as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). It has since been labeled as COVID-19. As of March 19, 2020, 230,588 cases have been reported and 9390 patients have died. In India, 173 patients were diagnosed with COVID-19 with 4 deaths reported. On March 11, 2020, the World Health Organization (WHO) has declared COVID-19 as a pandemic. In this issue of IJMPO, Tsang et al. have appropriately reviewed the current knowledge about symptomatology, rapid diagnosis, and treatment as well as prevention strategies for COVID-19.[1]

Here, we will summarize the current understanding and practical information to handle this deadly menace. The COVID-19 is transmissible in a community setting, and clusters of infection can be seen in people who return from countries with high infection.[2]



Publication History

Received: 20 March 2020

Accepted: 22 March 2020

Article published online:
23 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Tsang J, Bajpai J. Novel Coronavirus Infection – Knowns and Unknowns with Particular Reference to Oncology – Combating against COVID-19 with “COVID”. Indian J Med Paediatr Oncol 2020; DOI: 10.4103/ijmpo.ijmpo-95-20.
    CrossrefGoogle Scholar
  • 2 Pung R, Chiew CJ, Young BE, Chin S, Chen MI, Clapham HE. et al. Investigation of three clusters of COVID-19 in Singapore: Implications for surveillance and response measures. Lancet 2020; pii S0140-6736(20)30528-6. doi: 10.1016/S0140-6736(20)30528-6. [Epub ahead of print]
    Google Scholar
  • 3 Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls. Florida: StatPearls Publishing; 2020
    Google Scholar
  • 4 van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020. doi: 10.1056/NEJMc2004973. [Epub ahead of print]
    Google Scholar
  • 5 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020. doi: 10.1056/NEJMoa2002032. [Epub ahead of print]
    Google Scholar
  • 6 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; pii S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3. [Epub ahead of print]
    Google Scholar
  • 7 Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; pii S2213-2600(20)30079-5. doi: 10.1016/S2213-2600(20)30079-5. [Epub ahead of print]
    Google Scholar
  • 8 Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J. et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020. doi: 10.1056/NEJMc2005073. [Epub ahead of print]
    Google Scholar
  • 9 Liang W, Guan W, Chen R, Wang W, Li J, Xu K. et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21: 335-7
    CrossrefPubMedGoogle Scholar
  • 10 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177-9
    CrossrefPubMedGoogle Scholar
  • 11 Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382: 970-1
    CrossrefPubMedGoogle Scholar
  • 12 Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic Available from: [Last accessed on 2020 Mar 20]
    Google Scholar
  • 13 Indian Council of Medical Research (ICMR). Revised strategy of COVID-19 testing in India. https://www.mohfw.gov.in/pdf/ICMRrevisedtestingstrategyforCOVID.pdf Available from: [Last accessed on 2020 Mar 22]
    Google Scholar
  • 14 Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020; pii S1473-3099(20)30086-4. doi: 10.1016/S1473-3099(20)30086-4. [Epub ahead of print]
    Google Scholar
  • 15 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. doi: 10.1056/NEJMoa2001282. [Epub ahead of print]
    Google Scholar
  • 16 Guidelines on Clinical Management of COVID – 19. https://www.mohfw.gov.in/pdf/GuidelinesonClinicalManagementofCOVID1912020.pdf Available from: [Last accessed on 2020 Mar 20]
    Google Scholar
  • 17 Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16
    CrossrefPubMedGoogle Scholar
  • 18 Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Openlabel Non-Randomized Clinical Trial. https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf Available from: [Last accessed on 2020 Mar 22]
    Google Scholar
  • 19 Wang C, Li W, Drabek D, Okba NM, van Haperen R. A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv 2020.03.11.987958 2020; DOI: 10.1101/2020.03.11.987958.
    Google Scholar
  • 20 Advisory on Social Distancing Measure in View of Spread of COVID-19 Disease. https://www.mohfw.gov.in/pdf/SocialDistancingAdvisorybyMOHFW.pdf Available from: [Last accessed on 2020 Mar 20]
    Google Scholar
  • 21 Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW. et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 2020; 8: e488-96
    CrossrefPubMedGoogle Scholar
  • 22 Tondo L. Scientists say mass tests in Italian town have halted Covid-19 there Guardian. 2020
    Google Scholar